No label defined (Q32382)
Jump to navigation
Jump to search
No description defined
- Urologic oncology considerations in transgender and gender diverse patients.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
This review delves into the pressing issue of urologic oncology considerations within the transgender and gender-diverse (TGD) community. (English)
PURPOSE OF REVIEW (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
With estimates suggesting that TGD individuals constitute 0.3 to 0.5% of adults worldwide, and this number steadily rising, our review examines the barriers that impede the delivery of excellent quality care, particularly in the context of cancer diagnosis and treatment. (English)
PURPOSE OF REVIEW (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
Recent findings highlight disparities in cancer screening, diagnosis, and treatment access for TGD individuals. (English)
RECENT FINDINGS (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
These challenges are compounded by a dearth of research and the failure of healthcare systems to account for gender identity and its nuances in data collection. (English)
RECENT FINDINGS (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
Main themes in the literature include the impact of gender-affirming hormone therapy and surgery on cancer risk, challenges in prostate cancer screening and management, and considerations pertinent to testicular and other urological cancers in TGD patients. (English)
RECENT FINDINGS (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
The implications for clinical practice and research are profound and emphasize the need for multidisciplinary approaches that cater to the unique healthcare needs of TGD individuals. (English)
SUMMARY (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
This includes comprehensive strategies for inclusive and accurate data collection, alongside the development of evidence-based guidelines for cancer screening and management tailored specifically to this population. (English)
SUMMARY (English)
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved. (English)
2024
Juan (English)
Tinajero (English)
J
Tina (English)
Rashid (English)
T
6 August 2024
6 August 2024